首页> 美国卫生研究院文献>Radiation Oncology (London England) >Prognostic value of phosphorylated Raf kinase inhibitory protein at serine 153 and its predictive effect on the clinical response to radiotherapy in nasopharyngeal carcinoma
【2h】

Prognostic value of phosphorylated Raf kinase inhibitory protein at serine 153 and its predictive effect on the clinical response to radiotherapy in nasopharyngeal carcinoma

机译:磷酸化Raf激酶抑制蛋白在153位丝氨酸的预后价值及其对鼻咽癌放疗临床反应的预测作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundRadiation is an effective treatment against nasopharyngeal carcinoma (NPC). However, radioresistance-induced locoregional recurrence remains as a major cause of treatment failure. Therefore, radiosensitivity indicators prior to treatment should be developed to screen radioresistant patients. Previous studies revealed that RKIP (Raf kinase inhibitor protein) is associated with NPC prognosis and radiosensitivity. However, the relationship of p-Ser153 RKIP (RKIP in a phosphorylated form at residue serine153) expression with the effect of radiation and prognosis of NPC patients is not elucidated. Thus, these clinical implication of the phosphorylated RKIP in NPC has yet to be described.
机译:背景放射是一种有效的治疗鼻咽癌的方法。但是,放射抵抗引起的局部复发仍然是治疗失败的主要原因。因此,应在治疗前制定放射敏感性指标,以筛查放射线耐药的患者。先前的研究表明,RKIP(Raf激酶抑制剂蛋白)与NPC的预后和放射敏感性有关。然而,尚未阐明p-Ser153 RKIP(在残基丝氨酸153处为磷酸化形式的RKIP)表达与NPC患者的放射作用和预后的关系。因此,NPC中磷酸化RKIP的这些临床意义尚待描述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号